Experts hesitate on weight loss ETFs amid the obesity drug boom
Publishing timestamp: 2024-03-13 19:00:01
Summary
Two ETFs focused on weight loss companies are set to launch, with Novo Nordisk and Eli Lilly being the main holdings. Some experts question the relevance of weight loss ETFs, as only two companies dominate the U.S. obesity drug market. Thematic ETFs may be falling out of favor with investors, with single stocks potentially offering a stronger investment case.
Sentiment: NEUTRAL
Tickers: LLY, NVO, NOVO.B-DK, XLV,
Keywords: exchange-traded funds, novo nordisk a/s, stock markets, investment strategy, business news, health care select sector spdr fund, eli lilly and co, health care industry, markets, health, obesity,
Source: https://www.cnbc.com/2024/03/13/weight-loss-etfs-may-sit-out-obesity-drug-mania-experts-say.html